DLBCLsare broadly addicted to SIRT3, and SIRT3 deletion or inhibition efficientlykills DLBCL cells in vitro and in vivo.6 The previously reported SIRT3 inhibitor YC8-02 (Figure 1) was the first reported highlyactive SIRT3 inhibitor. This evidence concerns the gene SIRT3 and diffuse large B-cell lymphoma.